Robin C. Kramer

Executive Vice President and Chief Financial Officer (principal financial officer), Biogen

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Robin C. Kramer signed the annual report of Biogen as Executive Vice President and Chief Financial Officer (principal financial officer); the report was filed on February 6, 2026, the most recent filing in the record that ties Robin C. Kramer to the seat.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Biogen (BIIB) Biological Products, (No Diagnostic Substances)	Executive Vice President and Chief Financial Officer (principal financial officer)	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

February 6, 202610-K filed
Robin C. Kramer signed the annual report of Biogen on Form 10-K as Executive Vice President and Chief Financial Officer (principal financial officer), filed February 6, 2026.
/S/ ROBIN C. KRAMER Executive Vice President and Chief Financial Officer (principal financial officer)
[1] Annual report on Form 10-K by Biogen, filed with the SEC on February 6, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Biogen. U.S. Securities and Exchange Commission, EDGAR, filed February 6, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Robin C. Kramer wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.